Cyclooxygenase (COX) 2-derived prostaglandin E 2 (PGE 2 ) promotes colorectal carcinoma growth and invasion, and inhibition of COX2 by non-steroidal anti-inflammatory drugs is known to inhibit these processes. There is controversy regarding the effect of ligand activation of peroxisome proliferator-activated receptor (PPAR)-b/d on colon carcinogenesis, although collective evidence from independent laboratories suggest that ligand activation of PPARb/d leads to the induction of terminal differentiation coupled with inhibition of cell growth in a variety of models. The present study examined the hypothesis that ligand activation of PPARb/d and inhibition of COX2 attenuate colon cancer through independent mechanisms and that combining these two mechanisms will enhance this inhibition. Colon cancer was induced by administering azoxymethane to wild-type and PPARb/d-null mice. Cohorts of mice were treated with GW0742 (a PPARb/d ligand), nimesulide (a COX2 inhibitor) or a combination of GW0742 and nimesulide. Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARb/d by GW0742 had inhibitory effects. However, the combined treatment of GW0742 and nimesulide did not cause an enhancement in the attenuation of colon cancer. Mechanistically, the effects of these compounds occurred through independent mechanisms as increased levels of differentiation markers as a result of ligand activation of PPARb/d were not found with COX2 inhibition, and a reduction in PGE 2 levels resulting from COX2 inhibition was not observed in response to ligand activation of PPARb/d. Results from these studies effectively dissociate COX2 inhibition and PPARb/d activity during colon carcinogenesis.
Introduction
A growing body of evidence has linked cyclooxygenase (COX2) 2, an enzyme that catalyzes the conversion of arachidonic acid to prostaglandins, with colorectal cancer (CRC). Approximately 70-80% of human colorectal carcinomas exhibit increased levels of COX2 expression (1) . Previous studies using genetic and pharmacologic approaches suggest that COX2 plays a causal role in the development of CRC (2, 3) . In addition, COX2-specific inhibitors have been shown to inhibit cell growth in a number of tumors including colon, skin epidermal, gall bladder, esophageal adenocarcinoma and pancreatic cancer cells (4) (5) (6) (7) (8) . Selective inhibitors of COX2 have been shown to inhibit the growth of adenomatous polyps in patients with familial adenomatous polyposis, which helped to establish the basis for their use as drugs in the treatment and/or prevention of CRC (9) . Though they have been associated with anti-neoplastic activity in the colon, the mechanisms by which COX2 inhibitors exert their activities remain unclear. COX2 derived prostaglandin E 2 (PGE 2 ) affects numerous tumorigenic processes, including cell proliferation, motility, immune function and apoptosis (10) (11) (12) (13) (14) (15) . In addition, PGE 2 has been shown to prevent chemically induced attenuation of epithelial cell proliferation in a mouse model of colonic injury (16) . The primary mechanism by which PGE 2 exacerbates colon cancer is through binding to a family of G-protein coupled receptors known as prostaglandin type E receptors, which activate a signaling cascade that stimulates adenylate cyclase activity, leading to the accumulation of cyclic adenosine 3#,5#-monophosphate. Increased cyclic adenosine 3#,5#-monophosphate activates protein kinase A-cyclic AMP response elementbinding-dependent gene expression in tumor cells, leading to increased cell proliferation and inhibition of apoptosis (17) . Recent studies have suggested that PGE 2 may also activate tcf4/b-cateninmediated transcription, leading to increased expression of genes such as cyclin D, c-myc and VEGF, thereby increasing cell proliferation and angiogenesis (18) (19) (20) . Combined, these findings suggest that COX2 inhibitors exert their anti-CRC activity via inhibition of PGE 2 , which leads to attenuation of colonic cell proliferation and increased apoptosis. While COX2 inhibition has generally been thought to underlie the anti-CRC activity of non-steroidal anti-inflammatory drugs (NSAIDs) (21, 22) , several COX-independent mechanisms of action have also been described in cultured CRC cells (23) .
Some reports have suggested that peroxisome proliferator-activated receptor (PPAR)-b/d may also participate in prostaglandin-mediated signaling (24) (25) (26) (27) (28) (29) . However, this hypothesis remains speculative as other findings are inconsistent with the hypothesis linking COX2 activity and PPARb/d activation. For example, sulindac-mediated apoptosis occurs in HCT116 colon cancer cells, in the absence of PPARb/d expression (30) and activation of PPARb/d does not occur in cells over-expressing prostacyclin synthase (31) , suggesting that COX-derived PG1 2 is not an endogenous PPARb/d ligand. Further, there is no relationship between PPARb/d polymorphisms in humans and the ability of COX inhibition to attenuate colon cancer (32) and inhibition of chemically induced epithelial cancer by inhibition of COX activity is effective in the absence of PPARb/d expression (33) . Collectively, these observations suggest that COX activity and PPARb/d functions are independent.
A growing body of evidence indicates that PPARb/d attenuates CRC. For example, targeted deletion of the adenomatous polyposis coli alleles in mouse intestine results in reduced expression of PPARb messenger RNA (mRNA) and protein accompanied with the expected increase in the level of mRNA encoding c-myc and accumulation of b-catenin (34) . This is consistent with the findings that expression of PPARb/d in colon tumors from mouse and human models is lower as compared with normal colon epithelium (35, 36) . In the absence of PPARb/d expression, colon carcinogenesis is exacerbated in both genetic and a chemical mouse models of colon carcinogenesis (34, 36, 37) , and ligand activation of PPARb/d in the colon results in inhibition of colon polyp formation in azoxymethane (AOM)-treated mice by increasing terminal differentiation in the colon (36) . The latter finding is also supported by a number of reports from independent laboratories linking PPARb/d with inhibition of cell growth and/or terminal differentiation in a wide range of cell types (36, (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . Additionally, there is good evidence that PPARb/d mediates anti-inflammatory activity in a number of cell types (colon epithelium, macrophages, cardiomyocytes, immune cells, keratinocytes, myoblasts, endothelial cells and hepatocytes) (43, 45, 52, (57) (58) (59) (60) (61) (62) (63) (64) . Collectively, these data suggest that PPARb/d attenuates CRC via activation of differentiation pathways with a subsequent reduction in cell proliferation and induction of apoptosis. Indeed, ligand activation of PPARb/d inhibits AOM-induced colon tumors in a PPARb/d-dependent mechanism that is due to the induction of terminal differentiation (36) .
Combined, there is good evidence that inhibition of COX2 inhibits colon cancer by modulating prostaglandin-mediated signaling and that ligand activation of PPARb/d inhibits colon cancer by inducing terminal differentiation. This suggests that combining these two molecular pathways could effectively increase the efficacy of either targeted approach. This hypothesis is supported by a recent report showing that combining ligand activation of PPARb/d with the inhibition of COX enhances apoptosis and inhibits cell proliferation in human lung cancer cells (41) . The present studies examined the hypothesis that combining the two treatments will increase the efficacy of inhibiting colon carcinogenesis.
Materials and methods
Cell proliferation analysis in HCT116 colon carcinoma cells HCT116 colon carcinoma cells were obtained from American Type Culture Collection and maintained in McCoy's 5A medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum at 37°C and 5% carbon dioxide. For proliferation assays, cells were plated on 12-well dishes at a density of $500 000 cells per well 24 h prior to determining plating efficiency with a Z1 Coulter Particle CounterÒ at time 0 (Beckman Counter, Hialeah, FL). Cells were then serum starved for 24 h prior to ligand and nimesulide treatments. After this 24 h period, cells were maintained in respective culture medium with serum and treated with GW0742 for 24, 48 and 72 h at concentrations of 0 (dimethyl sulfoxide control) or 1 lM. This concentration of ligand was used because similar concentrations have been used by others, allowing for comparisons between these studies. In addition to ligand treatments, cells were treated with either the COX1/COX2 inhibitor indomethacin (Sigma-Aldrich, St Louis, MO) at a concentration of 600 lM or the COX2-specific inhibitor nimesulide (Sigma-Aldrich) at a concentration of 100 lM, either alone or in combination with GW0742. Cells were quantified every 24 h with a Z1 Coulter Particle CounterÒ (Beckman Counter). Triplicate samples for each treatment were used for each time point for every treatment, and each replicate was counted three times.
Colon cancer bioassay
Male wild-type and PPARb/d-null mice (50) (6-8 weeks of age, 10 mice per group) were injected intra-peritoneally with 10 mg AOM/kg body wt, once a week for 10 weeks as described previously (36) . Four cohorts of mice from both genotypes were divided into one of the following groups: control, GW0742 alone (5 mg/kg body wt), nimesulide alone (400 mg/kg diet) or combined GW0742 and nimesulide. The mice being treated with GW0742 were administered 5 mg GW0742/kg body wt by oral gavage five times per week for 22 weeks. The mice being treated with nimesulide were fed a diet containing 400 mg nimesulide/kg diet (Bioserv, Piscataway, NJ) ad libitum. Twenty-two weeks after the initial injection with AOM, mice were euthanized by overexposure to carbon dioxide. The colons were flushed with phosphatebuffered saline, and lesions were counted and measured by inspection under a dissecting microscope.
Short-term nimesulide and ligand treatments
Male wild-type and PPARb/d-null mice were divided into one of three groups: (i) treated by oral gavage with GW0742 (5 mg/kg) once per day for 5 days, (ii) fed the nimesulide diet (400 mg/kg diet) for 5 days or (iii) fed the nimesulide diet (400 mg/kg diet) combined with GW0742 (5 mg/kg) via gavage once per day for 5 days. Two hours prior to euthanasia by overexposure to carbon dioxide, mice were injected intra-peritoneally with bromodeoxyuridine (BrdU) at a dose of 100 mg/kg. Mice were euthanized 8 h after the last dose of GW0742. The colons were carefully dissected and flushed with saline, cut into 3 mm serial sections and fixed in 10% buffered neutral formalin. After 24 h of fixation in formalin, colons were transferred to 70% ethanol and subsequently embedded in paraffin and cut into 3-4 lm sections for histological analyses. For PGE 2 , protein and RNA analyses, sections of the colon were flash frozen in liquid nitrogen and stored at À80°C until ready for use.
BrdU analysis
Detection of BrdU-labeled cells was performed in the colon sections of shortterm treated mouse colons using immunohistochemical methods. Sections were deparaffinized and rehydrated, and endogenous peroxidase was blocked with 3% H 2 O 2 in methanol. Slides were incubated at 37°C for 30 min in a 0.08% trypsin solution for antigen retrieval, denatured by incubation in 2 N HCl at 37°C for 30 min and neutralized by incubation in 0.1 M borax for 10 min. Sections were blocked with 20% mouse serum for 30 min at room temperature, and subsequently blocked with Mouse-on-Mouse blocking reagent (Vector Laboratories, Burlingame, CA) for 1 h at room temperature. Primary mouse monoclonal BrdU antibody (Vector Laboratories) was applied to the sections at a 1:200 dilution and incubated at room temperature for 30 min. Slides were then incubated with secondary biotinylated anti-mouse IgG for (Vector Laboratories) 10 min at room temperature. These slides were incubated in avidin-biotin horseradish peroxidase (ABC kit, Vector Labarotories) for 5 min, followed by incubation in diaminobenzidine tetrahydrochloride for detection of positively labeled cells. The sections were counterstained with hematoxylin and visualized under a light microscope. BrdU-labeled colonocytes were quantified using light microscopy and labeling indices were quantified as a percentage of labeled cells per total cells in representative crypts counted.
Quantification of PGE 2 in colon and serum PGE 2 levels were measured in the colons of short-term ligand-treated mice using an enzyme-linked immunosorbent assay-based assay (Assay Designs, Ann Arbor, MI). Extraction of PGE 2 from colon and serum was done as described previously (65) . Tissues were homogenized briefly in prostaglandin extraction buffer [70% ethanol and 30% of 1 mM sodium phosphate (pH 4.0)] and incubated on ice for 30 min. All samples were then centrifuged at 3800 r.p.m. for 10 min, and the supernatant was collected. A fixed volume of each sample (250 ll) was dried under argon at 37°C and re-suspended in assay buffer. PGE 2 levels were determined following the manufacturer's recommended procedure and normalized to total protein content.
RNA analysis and real-time quantitative polymerase chain reaction
Total RNA was isolated from colon samples as described previously (36) . The mRNAs encoding angiogenin-related protein-like 4 (ANGPTL4), COX2 and adipocyte differentiation-related protein (ADRP) were quantified using realtime polymerase chain reaction (PCR) analysis. The cDNA was generated using 2.5 lg total RNA with MultiScribe Reverse Transcriptase kit (Applied Biosystems, Foster City, CA). Primers were designed for real-time PCR using the Primer Express software (Applied Biosystems). The sequence and GenBank accession numbers for the forward and reverse primers used to quantify mRNAs were COX2 (NM_011198) forward, 5#-TTGCTGTACAAGCAGT-GGCAAAGG-3# and reverse, 5#-TGCAGCCATTTCCTTCTCTCCTGT-3#; ANGPTL4 (NM_020581) forward, 5#-TTCTCGCCTACCAGAGAAGTTG-GG-3# and reverse, CATCCACAGCACCTACAACAGCAC-3#; and ADRP (NM_007408) forward, 5#-CACAAATTGCGGTTGCCAAT-3# and reverse, 5#-ACTGGCAACAATCTCGGACGT-3#. All mRNAs examined were normalized to the gene encoding GAPDH (BC083149) using the following primers: forward, 5#-GGTGGAGCCAAAAGGGTCAT-3# and reverse, 5#-GGTTCA-CACCCATCACAAACAT-3#. Real-time PCR reactions were carried out using SYBR green PCR master mix (Finnzymes, Espoo, Finland) in the iCycler and detected using the MyiQ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). The following conditions were used for PCR: 95°C for 15 s, 94°C for 10 s, 60°C for 30 s and 72°C for 30 s and repeated for 45 cycles. The PCR included a no template control reaction to control for contamination and/or genomic amplification. All reactions had .90% efficiency. Relative expression levels of mRNA were normalized to GAPDH and analyzed for statistical significance using one-way analysis of variance (Prism 4.0).
Quantitative western blot analysis
Protein samples were obtained from colon samples by homogenizing in 1Â RIPA buffer. Samples were then centrifuged at 14 000 r.p.m. at 4°C for 45 min and supernatants were collected. Fifty micrograms of protein from each sample was resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The samples were transferred onto a polyvinylidene difluoride membrane using an electroblotting method. After blocking in 5% milk in Tris buffered saline Tween-20, the membrane was incubated overnight at 4°C with primary antibody [COX2-(Santa Cruz Biotechnology, Santa Cruz, CA) or PPARc (Affinity BioReagents, Golden, CO)], followed by incubation with a biotinylated secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). Immunoreactive proteins were detected after incubation in [ 125 I]-labeled streptavidin (Amersham Biosciences, Piscataway, NJ) using phosphorimaging analysis. Hybridization signals for COX2 were normalized to the hybridization signals of the housekeeping protein, lactate dehydrogenase (Rockland, Gilbertsville, PA). Independent duplicate samples were used for analysis of each treatment group.
Chromatin immunoprecipitation assays
To confirm differential promoter occupancy on PPARb/d target genes after GW0742 treatment, chromatin immunoprecipitation assays were performed H.E.Hollingshead et al.
using DNA from colonic epithelial cells from control and ligand-treated mice. Wild-type and PPARb/d-null mice were treated with vehicle (corn oil) or GW0742 (5 mg/kg) via oral gavage 4 h prior to euthanasia. After euthanasia, colons were removed, flushed with saline and epithelial cells scraped from the mucosa using a razor blade. Cells were cross-linked by adding formaldehyde to a final concentration of 1% in 7.8 M N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid. Chromatin immunoprecipitation assays were performed as described previously (66) . Affinity-purified antibodies specific to cathepsin D (Santa Cruz Biotechnology) (negative control) or acetylated Histone H4 (Santa Cruz Biotechnology) were used for IP. No commercially available PPARb/d antibodies are suitable for immunoprecipitation (data not shown), precluding examination of PPARb/d promoter occupancy. Samples were PCR amplified with oligonucleotide primer pairs for the mouse 5# ANGPTL4 and ADRP proximal promoter elements using a standard PCR protocol. Primer sets for the ANGPTL4 upstream promoter region were designed based on analysis of PPREs located in the 5# upstream region. Primer pairs for the ANGPTL4 proximal promoter region were forward, 5#-ACGTCGCTTATTAGGTCG-CAAGGA-3# and reverse, 5#-AGTGGGAGGGAGAGCATTGGA-3#. Primer sets for the ADRP upstream promoter region were designed based on previous evaluation of a peroxisome proliferator response element located in the 5# upstream region spanning nucleotides À2004 to À1992 (67). Primer pairs for the ADRP proximal promoter region were forward, 5#-TCCTCCTTCCCTGGCA-GACAAA-3# and reverse, 5#-AGGAAGGTTGAGAACCACTGCTCT-3#.
Statistical analysis
Data were analyzed for statistical significance using analysis of variance and the Bonferroni post test (Prism 4.0).
Results
Ligand activation of PPARb/d and inhibition of COX enhance attenuation of cell proliferation in HCT116 colon cancer cells Cell proliferation was significantly decreased as early as 24 h after treatment in response to either indomethacin or nimesulide, and continued to decrease over the 72 h treatment period ( Figure 1A and B) . No significant change in cell proliferation was observed following GW0742 treatment in the first 24 h of exposure. However, a significant decrease in cell proliferation was observed in HCT116 cells after 48 h of GW0742 treatment ( Figure 1A and B) , and this inhibition in cell proliferation continued for the duration of the experimental period. Consistent with a previous report (41) , co-treatment of indomethacin or nimesulide with GW0742 resulted in an enhancement in the inhibition of cell proliferation as compared with either of the treatments alone ( Figure 1A and B) . Increased expression of mRNA encoding PPARb/d was found in response to both indomethacin and nimesulide Figure 1D ). These results suggest that ligand activation of PPARb/d with COX inhibition can increase the efficacy of colon carcinogenesis inhibition.
Ligand activation of PPARb/d and inhibition of COX2 attenuate colon polyp multiplicity and/or cell proliferation independently Administration of GW0742 (5 mg/kg, five times per week, 22 weeks) did not result in a significant decrease in colon polyp number, consistent with previous findings (36) . In contrast, dietary nimesulide caused a significant decrease in colon polyp number, consistent with previous work by others (68) (Figure 2A ). Co-treatment with GW0742 and nimesulide did not result in an enhancement in chemoprevention. Similar to previous reports, more colon polyps were found in PPARb/d-null mice as compared with similarly treated wild-type animals (36,37) (Figure 2A) . Interestingly, dietary nimesulide treatment resulted in a significant decrease in colon polyp formation in PPARb/d-null mice as compared with control and GW0742-treated PPARb-null mice (Figure 2A) . No difference in the expression of mRNA encoding PPARb/d in colon was found between any of the treatment groups ( Figure 1E ). Additionally, no difference in the expression of PPARc was observed between any of the treatment groups ( Figure 1F) .
A short-term experiment revealed that ligand activation of PPARb/ d with GW0742 in wild-type mice caused a significant decrease in cell proliferation, and this effect was not observed in similarly treated PPARb-null mice ( Figure 2B ). Nimesulide treatment also resulted in a significant decrease in cell proliferation in wild-type mice but not in PPARb/d-null mice ( Figure 2B, supplementary Figure 1 is available at Carcinogenesis Online). Co-treatment with GW0742 and nimesulide did not enhance the reduction of cell proliferation ( Figure 2B , supplementary Figure 1 is available at Carcinogenesis Online).
Nimesulide inhibits COX2 activity in the colon and GW0742 does not Nimesulide treatment caused a significant decrease in the level of PGE 2 , and this decrease occurred in both wild-type and PPARb/d-null mice ( Figure 3A) , demonstrating that nimesulide treatment inhibited COX2. In contrast, GW0742 treatment had no effect on the level of colonic PGE 2 in either genotype ( Figure 3A) . In addition, co-treatment with GW0742 and nimesulide did not cause an enhancement in the reduction of PGE 2 . The level of colonic COX2 mRNA and protein were unchanged in either nimesulide or GW0742-treated wild-type or PPARb/d-null mice ( Figure 3B and C) .
Ligand activation of PPARb/d directly modulates target gene expression associated with terminal differentiation and inhibition of metastasis
The mRNA encoding ANGPTL4 and ADRP were increased by GW0742 treatment in wild-type mice and this increase was not observed in similarly treated PPARb/d-null mice ( Figure 4A ). This demonstrates that GW0742 causes increased expression of these PPARb/d target genes. Increased expression of these PPARb/d target genes was not found after nimesulide treatment ( Figure 4A ). Similarly, ligand activation of PPARb/d in the presence of the COX2 inhibitor nimesulide did not significantly alter the increase in ADRP expression, although a marginal enhancement of ANGPTL4 mRNA was found with co-treatment ( Figure 4A ). Neither of these changes observed with co-treatment were found in PPARb/d-null mice. Since mRNA encoding ADRP (a marker of differentiation in the colon) was upregulated by ligand activation of PPARb/d in the colon ( Figure 4A ), this suggests that PPARb/d activation induces differentiation in the colon as shown previously (36) . In contrast, nimesulide treatment did not influence mRNA encoding ADRP ( Figure 4A ), suggesting that COX2 inhibition does not have a role in modulating terminal differentiation in the colon.
To demonstrate that induction of ANGPTL4 and ADRP is mediated by direct transcriptional modulation, chromatin immunoprecipitation analysis using an acetylated histone antibody was performed as no commercially available PPARb/d antibodies are suitable for IP (data not shown). Immunoprecipitation of chromatin with the affinity-purified anti-acetylated histone H4 antibody showed increased promoter occupancy on both the ANGPTL4 and ADRP promoter in wild-type mouse colon after treatment with GW0742, and this effect was not found in either control or ligand-treated PPARb/d-null samples (Figure 4B) . This is consistent with PPARb/d-dependent increased activity of histone acetyl transferase, which occurs to facilitate histone remodeling, allowing for ligand activated PPARb/d to up-regulate target genes.
Discussion
The effect of ligand activation of PPARb/d on colon carcinogenesis remains controversial due to disparities in the literature. Thus, it is essential to clarify and delineate specific mechanisms resulting from ligand administration. A number of recent reports in the literature suggest that PPARb/d is a target of the COX2 pathway and promotes CRC growth and invasion. However, these reports are inconsistent with data showing that PPARb/d represses inflammation, induces differentiation and suppresses cell proliferation, effects one would predict would lead to the attenuation of cancer. Findings from the present studies address three general areas of interest: (i) the role of PPARb/d in modulating COX-dependent activities, (ii) the effect of ligand activation of PPARb/d in a colon-specific carcinogenic model and (iii) whether combining ligand activation of PPARb/d with inhibition of COX2 will increase the efficacy of chemoprevention. 
Dissociation of PPARb/d activity from COX2 inhibition
The current findings confirm a direct role of ligand activation of PPARb/d in differentiation in the colon, and more importantly distinguish COX2 and PPARb/d signaling as distinct molecular pathways, independent of each other.
In 1999, it was suggested that PPARb/d was a downstream target of the APC/b-catenin/tcf4 pathway (26) . This and other observations led to the hypothesis that one mechanism by which inhibition of COX2-inhibited colon cancer was by reducing COX-derived PPARb/d ligands, which putatively led to increased PPARb/d transcription that mediated increased cell growth of colon tumors. This idea was supported by a number of related observations including that inhibition of COX activity by sulindac can inhibit PPARb/d activity and overexpression of PPARb/d in HCT116 cells prevents sulindac-mediated apoptosis (26) . Inhibition of COX by sulindac is also reported to down-regulate PPARb/d in HT29 cells and lead to an overall increase in the level of apoptosis (69) . However, results from the present studies and many others as well are inconsistent with the hypothesis that inhibition of colon cancer by COX2 inhibition is mediated in part by reducing COX-derived PPARb/d ligands, which limits PPARb/d transcription that facilitates increased cell growth of colon tumors. The combined observations from the present studies showing that inhibition of colon-specific carcinogenesis by inhibition of COX2 activity by nimesulide occurs in the absence of PPARb/d expression coupled with the observation that inhibition of chemically induced skin cancer occurs in mice that do not express a functional PPARb/d (33) dissociates the effect of COX inhibition and ligand activation of PPARb/d in tumorigenesis. Further, there is strong evidence that PPARb/d is not a downstream target of the APC/b-catenin/tcf pathway (34) (35) (36) 70) . Recent findings also show that PGI 2 does not activate PPARb/d transcription, as over-expression of prostacyclin synthase does not increase PPARb/d activity (31) . HCT116 cells lacking PPARb/d are also not resistant to sulindac-mediated apoptosis (30) , which is of interest because this finding comes from the same lab that originally suggested that PPARb/d is linked to sulindac-induced apoptosis (26) and is inconsistent with a more recent report (69) . It is also important to note that there is no correlation between PPARb/d polymorphisms and the ability of NSAIDs to inhibit colon cancer in humans (32) . Thus, these findings strongly suggest that the mechanisms underlying chemoprevention of colon cancer by inhibition of COX2 activity is more probably due to decreased PGE 2 signaling and related mechanisms, but are not mediated by PPARb/d. However, it also remains possible that inhibition of cell growth and tumorigenesis observed in these studies by inhibition of COX2 are mediated in part through mechanisms that are independent of PGE 2 as anti-tumorigenic effects of COX2 inhibitors are found in COX2-null mice (reviewed in ref. 71) .
The recent hypothesis that NSAID-induced apoptosis is mediated by suppression of PPARb/d expression (69) is also not supported by the present findings. No decrease in PPARb/d was found in HCT116 cells by either indomethacin or nimesulide. Similarly, no changes in PPARb/d expression were found in colonocytes after exposure to the COX2 inhibitor nimesulide in vivo. This demonstrates that an NSAIDinduced change in PPARb/d expression that putatively modulates apoptosis is not consistently observed. Indeed, increased expression of PPARb/d was found in response to NSAIDs, consistent with results obtained from treating renal cell carcinomas with NSAIDs (49) . The reason for these differences could be due to differences in model systems (HT29 cells versus HCT116 cells), but the lack of change in an in vivo cancer model indicates that PPARb/d expression is not modulated by NSAIDs.
The second important finding from the present studies is the demonstration that ligand activation of PPARb/d directly increased expression of a differentiation-related target gene (ADRP) and inhibited replicative DNA synthesis in colonocytes, but did not potentiate tumorigenesis as reported by others (72) . Treatment with GW0742 in wild-type mice with a dose of 5 mg/kg did not result in significant reduction of colon polyp formation, consistent with a previous report (36) . However, short-term treatment with this dose of ligand caused a PPARb/d-dependent inhibition of cell proliferation in the colon as determined by relative BrdU incorporation. Deletion of PPARb/d expression also resulted in an increase in the average polyp number, as shown previously (36, 37) . The protective nature of PPARb/d is probably due to the direct modulation of terminal differentiation as shown in previous studies (36) , which did not occur in response to inhibition of COX2 activity. Alternatively, ligand activation of PPARb/d could inhibit tumorigenesis via induction of ANGPTL4, which can inhibit tumor cell motility and invasiveness (73) . These observations are consistent with work showing that treatment with two PPARb/d-specific ligands (GW0742 and GW501516) in three different human colon cancer cell lines (HCT116, HT29 and LS-174T) and one human liver cell line (HepG2) does not result in an increase of cell proliferation (74) and two independent studies showing that GW501516 does not cause increased cell proliferation in HT29 cells (75, 76) . The observed inhibition of cell growth found in HCT116 cells in the present studies and inhibition of colon tumorigenesis reported in a previous study (36) after ligand activation of PPARb/d is consistent with a number of other studies showing PPARb/d-mediated inhibition of cell growth in a number of different model systems (36, (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . The present studies cannot determine why previous work by others suggests that ligand activation of PPARb/d potentiates colon carcinogenesis (72) . However, it is worth noting that these studies (72) did not examine colon cancer using the colonspecific carcinogen AOM, and more importantly used mice on a mixed genetic background. Thus, it is possible that these results are confounded by the presence of modifiers of min alleles (77) (78) (79) , which can significantly modulate the incidence of intestinal tumorigenesis in the APC min mouse model. It is also worth noting that the variation observed in the average number of intestinal polyps simply within control APC min mice from one laboratory ranges from 30 to .100 (27, 72, 80) , while treatment-related effects exhibit similar large variation. This raises serious concern regarding the suitability of the APC min mouse model for studying the role of PPARb/d in colon cancer. Thus, it remains possible that the contention that PPARb/d potentiates colon carcinogenesis is incorrect due to inherent limitations of the model. Combined, there is good evidence to suggest that both inhibition of COX2 activity and ligand activation of PPARb/d can both inhibit colon carcinogenesis, which supports the hypothesis that combining these two approaches will increase the efficacy of chemoprevention, which was also examined in these studies.
Interestingly, combining ligand activation of PPARb/d with inhibition of COX2 either additively or synergistically inhibited cell growth of HCT116 cells, consistent with the proposed hypothesis and similar to findings made in a lung tumor cell line (41) . The mechanisms underlying this effect are uncertain but could include a synergistic or additive effect resulting from the combined effect of PPARb/ddependent induction of terminal differentiation and inhibition of cell growth (81) coupled with NSAID-mediated suppression of PGE 2 signaling or NSAID modulation of COX-independent activities. Additionally, since PPARs and NSAIDs such as nimesulide can both inhibit nuclear factor kappa beta activity (82, 83) , it is possible that combining ligand activation of PPARb/d with COX2 inhibitors more effectively interferes with nuclear factor kappa beta signaling that leads to enhanced inhibition of cell growth. The effect of ligand activation of PPARb/d and COX2 inhibition was also examined using a mouse colon cancer model. Dietary nimesulide treatment resulted in a significant decrease in COX2 activity, colon polyp formation and cell proliferation in both genotypes. This is consistent with past work showing that inhibition of chemically induced skin cancer by sulindac is independent of PPARb/d (33) . Co-treatment of GW0742 and nimesulide did not improve the inhibition of colon polyp formation or cell proliferation and no changes in PGE 2 levels were observed as a result of co-treatment with nimesulide and GW0742. Thus, despite promising data obtained from in vitro analysis, combining ligand activation of PPARb/d with inhibition of COX2 did not improve colon cancer chemoprevention at the doses examined in this work. It is unclear why the in vitro findings, suggesting that COX2 inhibitors work additively or synergistically with PPARb/d ligands to inhibit cell proliferation, are inconsistent with the in vivo findings showing no combinatorial effects between the two molecular targets. It remains possible that this H.E. Hollingshead et al. is due in part to species-specific differences between mouse and human, which could include differences in the ability to induce terminal differentiation, modulate COX2 activities and/or differences in nuclear factor kappa beta signaling. It is also possible that an additive or synergistic effect could be observed in the mouse model by varying the amounts of compounds, in particular by increasing the PPARb/d ligand. Further research is necessary to elucidate the mechanisms for these possible species-specific disparities or the possible additive or synergistic effects of these two compounds.
Collectively, the results of this study clearly distinguish COX2 and PPARb/d signaling as functionally distinct pathways. There are many reports in the literature that show that ligand activation of PPARb/d mediates cellular terminal differentiation, leading to inhibition of cell proliferation. This supports the hypothesis that PPARb/d attenuates a number of cancers. The present findings are highly inconsistent with the idea that PPARb/d potentiates the development of colon cancer via the COX2 pathway, and it gives strong evidence that PPARb/d attenuates colon cancer in a mechanism independent from that of the COX2 pathway. Further studies should be undertaken to examine the idea that combining ligand activation of PPARb/d with COX2 inhibitors and/or other molecular targets could lead to establishing chemotherapeutic/chemopreventive approaches with greater efficacy than currently available for the treatment of colon cancer.
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